Ultragenyx Pharmaceutical宣布其基因疗法Rebisufligene Etisparvovec的上市许可申请获欧洲药品管理局受理

美股速递
Oct 02

Ultragenyx Pharmaceutical Inc(简称Ultragenyx Pharmaceutical)今日宣布,其针对Rebisufligene Etisparvovec基因疗法的上市许可申请(MAA)已通过欧洲药品管理局(EMA)的验证。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10